Get started
Author

Hsiuanlin Wu

Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
2023 · Silvio Danese, Remo Panaccione, et al. · Journal of Crohn s and Colitis · 49
PDF
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
2024 · Bruce E. Sands, Geert D’Haens, et al. · Clinical Gastroenterology and Hepatology · 22
Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
2023 · Alessandro Armuzzi, Raymond K. Cross, et al. · Clinical Gastroenterology and Hepatology · 20
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis
2024 · Miguel Regueiro, Britta Siegmund, et al. · Inflammatory Bowel Diseases · 4
PDF
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial
2025 · Bruce E. Sands, David T. Rubin, et al. · The American Journal of Gastroenterology · 3
950 Long-term Safety of 3 Years of Ozanimod in Moderately to Severely Active Ulcerative Colitis: an Interim Analysis of the True North Open-label Extension
2023 · Maria T. Abreu, Silvio Danese, et al. · Gastroenterology · 2
PDF
S1476 Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
2024 · Bincy P. Abraham, Randy Longman, et al. · The American Journal of Gastroenterology · 1
P98 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the true north open-label extension study
2024 · Geert D’Haens, Bruce E Sands, et al. · Poster presentations · 1
Su1771 SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
2024 · Corey A. Siegel, David T. Rubin, et al. · Gastroenterology · 1
S906 Efficacy and Durability of Ozanimod by Baseline Endoscopic Disease Activity in Advanced Therapy–Naive Ulcerative Colitis Patients Suboptimally Controlled on Conventional Therapies
2023 · David T. Rubin, Britta Siegmund, et al. · The American Journal of Gastroenterology · 1
S901 Group-Based Trajectory Modeling to Identify Response Patterns to Ozanimod Treatment in Patients With Ulcerative Colitis
2023 · Parambir S. Dulai, Brian G. Feagan, et al. · The American Journal of Gastroenterology · 1
Tu1725 EFFECTS OF OZANIMOD ON HISTOLOGIC REMISSION AND MUCOSAL HEALING OVER 3 YEARS OF CONTINUOUS TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
2023 · Maria T. Abreu, Silvio Danese, et al. · Gastroenterology · 1
P609 Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study
2023 · J F Colombel, D T Rubin, et al. · Journal of Crohn s and Colitis · 1
PDF
S1441 Delayed Response to Ozanimod in Patients with Moderate vs Severe Endoscopic Disease: 4-Year Interim Analysis of the True North Open-Label Extension Study
2024 · Douglas C. Wolf, Raymond K. Cross, et al. · The American Journal of Gastroenterology
S1342 Impact of Baseline Disease Duration on Ozanimod Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 True North Study
2024 · Gary R. Lichtenstein, Geert R. D'Haens, et al. · The American Journal of Gastroenterology
S1200 Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
2024 · Raymond K. Cross, Silvio Danese, et al. · The American Journal of Gastroenterology
Su1766 OZANIMOD IS MORE EFFECTIVE IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH ENDOSCOPICALLY MODERATE VS SEVERE DISEASE REGARDLESS OF BASELINE PATIENT-REPORTED OUTCOMES OR PRIOR IMMUNOMODULATOR EXPOSURE
2024 · Jean Frederic Colombel, Stephen B. Hanauer, et al. · Gastroenterology
Su1791 DURABILITY OF RESPONSE IN DELAYED RESPONDERS TO OZANIMOD IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGICS: 3-YEAR UPDATE FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
2024 · Miguel D. Regueiro, Geert D'Haens, et al. · Gastroenterology
S1027 Impact of Prior Biologic Exposure on the Durability of 3-Year Continuous Ozanimod Treatment
2023 · Jean-Frederic Colombel, Anita Afzali, et al. · The American Journal of Gastroenterology
S894 Effects of Early Mucosal Healing at Week 10 Using Stringent Criteria in Patients With Ulcerative Colitis Treated With Ozanimod on Clinical Outcomes at Week 52
2023 · Jordan Axelrad, Ailsa Hart, et al. · The American Journal of Gastroenterology
S933 Durability of Symptomatic and Clinical Outcomes in Ozanimod-Treated Patients by Endpoints of Increasing Objectivity at True North Week 52: Interim Analysis of the True North Open-Label Extension Study
2023 · Maria T. Abreu, Remo Panaccione, et al. · The American Journal of Gastroenterology
S893 Impact of Prior Biologic Exposure on the Long-Term Durability of Clinical and Mucosal Efficacy in Patients With Ulcerative Colitis Treated With Ozanimod
2023 · Jordan Axelrad, Maia Kayal, et al. · The American Journal of Gastroenterology
S852 Long-Term Clinical and Endoscopic Outcomes in True North Week 52 Clinical Remitters Over 3 Years of Treatment With Ozanimod: An Interim Analysis of the True North Open-Label Extension Study
2023 · Anita Afzali, David T. Rubin, et al. · The American Journal of Gastroenterology
Tu1742 ENDOSCOPIC, HISTOLOGIC, AND COMBINED OUTCOMES WITH REINITIATION OF OZANIMOD AFTER TEMPORARY DISCONTINUATION: 2-YEAR INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
2023 · Miguel D. Regueiro, Axel Dignass, et al. · Gastroenterology
Tu1745 ACHIEVEMENT AND MAINTENANCE OF ENDOSCOPIC, HISTOLOGIC, AND COMBINED OUTCOMES AFTER EXTENDED INDUCTION IN WEEK 10 NONRESPONDERS OF OZANIMOD: 2-YEAR INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
2023 · Michael V. Chiorean, Jean Frederic Colombel, et al. · Gastroenterology
Works count: 26
Citation count: 107
H-index: 4
I10-index: 3
Year
Topic
Type